MA32405B1 - SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION - Google Patents

SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION

Info

Publication number
MA32405B1
MA32405B1 MA33445A MA33445A MA32405B1 MA 32405 B1 MA32405 B1 MA 32405B1 MA 33445 A MA33445 A MA 33445A MA 33445 A MA33445 A MA 33445A MA 32405 B1 MA32405 B1 MA 32405B1
Authority
MA
Morocco
Prior art keywords
methyl
triazin
quinolin
imidazo
fluoro
Prior art date
Application number
MA33445A
Other languages
Arabic (ar)
English (en)
Inventor
Lingkai Weng
Lei Qiao
Jiacheng Zhou
Pingli Liu
Yongchun Pan
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41058602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32405(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA32405B1 publication Critical patent/MA32405B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des sels d'acide dichlorhydrique et d'acide dibenzènesulfonique de l'inhibiteur de c-met kinase, le 2-fluoro-n-méthyl-4-[7-(quinoléin-6-ylméthyl)-imidazo[1,2-b][1,2,4]- triazin-2-yl]benzamide, et leurs compositions pharmaceutiques, utiles dans le traitement du cancer et d'autres maladies associées au dérèglement des voies des kinases. La présente invention concerne en outre des procédés et des intermédiaires de préparation du 2-fluoro-n-méthyl-4-[7-(quinoléin-6-ylméthyl)imidazo[1,2-b][1,2,4]- triazin-2-yl]benzamide et de ses sels.
MA33445A 2008-05-21 2010-12-20 SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION MA32405B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5499508P 2008-05-21 2008-05-21
PCT/US2009/044622 WO2009143211A2 (fr) 2008-05-21 2009-05-20 Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation

Publications (1)

Publication Number Publication Date
MA32405B1 true MA32405B1 (fr) 2011-06-01

Family

ID=41058602

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33445A MA32405B1 (fr) 2008-05-21 2010-12-20 SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION

Country Status (30)

Country Link
US (7) US8420645B2 (fr)
EP (2) EP2300455B1 (fr)
JP (2) JP6022158B2 (fr)
KR (1) KR101706784B1 (fr)
CN (4) CN113248510B (fr)
AR (3) AR071873A1 (fr)
BR (1) BRPI0912882A2 (fr)
CA (1) CA2724742C (fr)
CL (1) CL2009001250A1 (fr)
CO (1) CO6300934A2 (fr)
CY (1) CY1119813T1 (fr)
DK (1) DK2300455T3 (fr)
EA (1) EA021364B1 (fr)
EC (1) ECSP10010685A (fr)
ES (1) ES2643363T3 (fr)
HK (1) HK1251568A1 (fr)
HR (1) HRP20171528T1 (fr)
HU (1) HUE034716T2 (fr)
IL (3) IL209229A (fr)
LT (1) LT2300455T (fr)
MA (1) MA32405B1 (fr)
MX (3) MX2010012718A (fr)
MY (3) MY187131A (fr)
NZ (2) NZ602791A (fr)
PL (1) PL2300455T3 (fr)
PT (1) PT2300455T (fr)
SI (1) SI2300455T1 (fr)
TW (1) TWI472529B (fr)
WO (1) WO2009143211A2 (fr)
ZA (1) ZA201008212B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
WO2009143211A2 (fr) 2008-05-21 2009-11-26 Incyte Corporation Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
DE102013100596B4 (de) 2012-01-27 2023-09-07 Samsung Electronics Co. Ltd. Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
EP3964513A1 (fr) * 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
WO2016011658A1 (fr) * 2014-07-25 2016-01-28 Novartis Ag Polythérapie
EA039220B1 (ru) * 2014-07-25 2021-12-20 Новартис Аг СОСТАВ ТАБЛЕТКИ 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CA2979215A1 (fr) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions et procedes d'activation de la signalisation dependante de « stimulateur de genes d'interferon »
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
AU2017213154B2 (en) 2016-01-27 2023-02-02 Universität Zürich Use of GABAA receptor modulators for treatment of itch
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
WO2019204446A1 (fr) * 2018-04-18 2019-10-24 Neurocycle Therapeutics, Inc. Composés modulateurs allostériques positifs à gabaa, procédés de production et d'utilisations associés
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2021053559A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021165818A1 (fr) * 2020-02-17 2021-08-26 Novartis Ag Procédé et intermédiaires pour la préparation de 2-fluoro-n-méthyl-4-[7-quinolin-6-yl-méthyle)-imidazo[1,2-b][1,2,4]triazin-2 yl]benzamide
CN115697407A (zh) * 2020-06-02 2023-02-03 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
WO2022007752A1 (fr) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un composé benzamide et de son dichlorhydrate et procédé de préparation correspondant
WO2022063869A2 (fr) * 2020-09-24 2022-03-31 Merck Patent Gmbh Composés pour le traitement d'infections virales
CN112480017A (zh) * 2020-11-13 2021-03-12 金仓(上海)医药生物科技有限公司 一种3-氨基-1,2,4-三嗪的制备方法
CN114853762B (zh) * 2021-02-03 2026-03-06 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
TW202327569A (zh) 2021-09-01 2023-07-16 瑞士商諾華公司 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (fr) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Méthodes et matériels pour le traitement du cancer
CN119775203B (zh) * 2024-11-29 2025-11-14 河北科技大学 一种卡马替尼中间体6-(3,3-二乙氧基丙基)喹啉的合成方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4220450A (en) 1978-04-05 1980-09-02 Syva Company Chemically induced fluorescence immunoassay
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
DE3421029C2 (de) 1984-06-06 1986-04-24 Walter Steinhausen Mathis Verfahren und Vorrichtung zum trockenen Bedrucken eines Werkstückes unter Verwendung einer Heißprägefolie
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
MXPA01007019A (es) 1999-11-10 2002-09-18 Johnson & Johnson 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
ES2195943T3 (es) 1999-11-12 2003-12-16 Neurogen Corp Compuestos heteroaromaticos biciclicos y triciclicos.
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
DE60210755T2 (de) 2001-03-09 2006-11-16 Pfizer Products Inc., Groton Triazolopyridine als entzündungshemmende mittel
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
US20050090498A1 (en) 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
EP1481977A4 (fr) 2002-03-01 2006-02-01 Astellas Pharma Inc Compose heterocyclique azote
AU2003223295A1 (en) 2002-03-19 2003-10-08 Merck And Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA05002123A (es) 2002-08-30 2005-06-06 Pfizer Prod Inc Nuevos procedimientos e intermedios para preparar triazolo-piridinas.
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
ATE473980T1 (de) 2002-12-18 2010-07-15 Vertex Pharma Triazolopyridazine als proteinkinase-inhibitoren
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
JPWO2005002590A1 (ja) 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
CA2529622A1 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Hydrazides d'indolinone utilises en tant qu'inhibiteurs du recepteur c-met
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
CA2534292A1 (fr) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Imidazopyrimidines substituees pour la prevention et le traitement du cancer
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
EP1697352B1 (fr) 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated Compositions d'imidazole substitue par 4-azole utilisees comme inhibiteurs de c-met recepteur tyrosine kinase
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
US7144889B2 (en) 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005070891A2 (fr) 2004-01-23 2005-08-04 Amgen Inc Composes et leurs procedes d'utilisation
WO2005073224A2 (fr) 2004-01-23 2005-08-11 Amgen Inc Composes et methodes d'utilisation de ces derniers
CA2556404A1 (fr) 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. Derive azote de noyau heteroaromatique fusionne
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
WO2005121125A1 (fr) 2004-06-09 2005-12-22 Pfizer Inc. Composes heteroaryle a liaison ether
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
JP4935357B2 (ja) 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
AU2006247833A1 (en) 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2009500451A (ja) 2005-07-11 2009-01-08 スミスクライン ビーチャム コーポレーション ピラノピリジン化合物
WO2007015866A2 (fr) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
EP1910369A1 (fr) 2005-07-29 2008-04-16 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu inhibiteurs de lck
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
PT1966214T (pt) 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
JP5200939B2 (ja) 2005-12-23 2013-06-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式ヘテロアリール化合物
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
NZ575548A (en) * 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
WO2008058126A2 (fr) 2006-11-06 2008-05-15 Supergen, Inc. Dérivés d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de protéines kinases
KR101532256B1 (ko) * 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
CN101678014B (zh) 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
WO2009143211A2 (fr) 2008-05-21 2009-11-26 Incyte Corporation Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ

Also Published As

Publication number Publication date
CA2724742A1 (fr) 2009-11-26
EA021364B1 (ru) 2015-06-30
HK1251568A1 (en) 2019-02-01
EP2300455A2 (fr) 2011-03-30
CN103936743B (zh) 2018-04-24
AR123240A2 (es) 2022-11-09
ES2643363T3 (es) 2017-11-22
US10245265B2 (en) 2019-04-02
TW201008943A (en) 2010-03-01
TWI472529B (zh) 2015-02-11
EA201071337A1 (ru) 2011-06-30
DK2300455T3 (en) 2017-10-30
IL209229A0 (en) 2011-01-31
US20170258800A1 (en) 2017-09-14
US12427154B2 (en) 2025-09-30
NZ602791A (en) 2014-04-30
AR111428A2 (es) 2019-07-10
CN113248510A (zh) 2021-08-13
IL249651A0 (en) 2017-02-28
JP6022158B2 (ja) 2016-11-09
WO2009143211A2 (fr) 2009-11-26
MY187131A (en) 2021-09-02
PT2300455T (pt) 2017-10-19
HRP20171528T1 (hr) 2017-11-17
NZ589622A (en) 2012-10-26
IL209229A (en) 2015-11-30
IL229229A (en) 2017-05-29
US20210128568A1 (en) 2021-05-06
CN102083814B (zh) 2014-04-23
AR071873A1 (es) 2010-07-21
US20130289036A1 (en) 2013-10-31
MX368802B (es) 2019-10-17
KR20110037962A (ko) 2011-04-13
IL229229A0 (en) 2013-12-31
US10799509B2 (en) 2020-10-13
US20190167692A1 (en) 2019-06-06
PL2300455T3 (pl) 2018-02-28
EP2300455B1 (fr) 2017-07-19
CN102083814A (zh) 2011-06-01
SI2300455T1 (sl) 2017-12-29
MX2019011954A (es) 2019-10-30
AU2009249154A1 (en) 2009-11-26
US8901123B2 (en) 2014-12-02
CL2009001250A1 (es) 2010-02-05
US11452726B2 (en) 2022-09-27
BRPI0912882A2 (pt) 2017-05-16
US20230098850A1 (en) 2023-03-30
MX393622B (es) 2025-03-24
CN108586463A (zh) 2018-09-28
IL249651A (en) 2017-10-31
EP3287449A2 (fr) 2018-02-28
CY1119813T1 (el) 2018-06-27
AU2009249154B2 (en) 2014-12-11
JP2015145378A (ja) 2015-08-13
EP3287449A3 (fr) 2018-05-30
CO6300934A2 (es) 2011-07-21
MY199552A (en) 2023-11-07
CA2724742C (fr) 2016-07-19
ECSP10010685A (es) 2011-04-29
US8420645B2 (en) 2013-04-16
CN113248510B (zh) 2025-01-17
JP2011520976A (ja) 2011-07-21
KR101706784B1 (ko) 2017-02-14
WO2009143211A3 (fr) 2010-03-04
MX2010012718A (es) 2011-04-04
HUE034716T2 (hu) 2018-02-28
MY155565A (en) 2015-10-30
LT2300455T (lt) 2017-11-10
JP6105653B2 (ja) 2017-03-29
US20150148348A1 (en) 2015-05-28
CN103936743A (zh) 2014-07-23
US20090291956A1 (en) 2009-11-26
ZA201008212B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MA32405B1 (fr) SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION
CY2020006I1 (el) Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk
FR19C1033I2 (fr) Derives phosphores servant d'inhibiteurs de kinase
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
DK2338487T3 (da) Kombinationsterapi med PARP-inhibitorer
SMAP200800022A (it) Benzimidazoli sostituiti come inibitori delle chinasi
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
EA201691862A2 (ru) Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EP2432473A4 (fr) Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de kinases
CR11650A (es) DERIVADOS BICICLICOS HETEROCICLICOS O ESPIROBICICLICOS HETEROCICLICOS ENLAZADOS, DE PIRAZOLO[1,5-a] PIRIMIDINAS, PROCEDIMIENTOS PARA SU PREPARACION Y USOS DE LOS MISMOS
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
CY1116007T1 (el) Ενωση ιμιδαζο[4,5-c]κινολιν-2-ονης και χρηση της ως διπλος αναστολεας της ρ13 κινασης/mtor
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA200870410A1 (ru) Антагонисты киназы
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
CU24155B1 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
EP2616477A4 (fr) Dérivés de diméthyl-estradiol 6-substitués à titre d'agonistes d'er-bêta
BR112012002801A2 (pt) derivados de 3-heteroarilmetil-imidazo[1,2-b]piridazin-6-ila como moduladores de tirosina quinase c-met